All In Biotech

Drug Trial Radar · NCT04993391

AP-L1898 Capsule in Patients With Non-small Cell Lung Cancer

A Dose-escalation, Dose-extension and Efficacy-extension, Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Preliminary Efficacy of AP-L1898 Capsule for the Treatment of the Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

32

Actual

Start

Jul 14, 2021

Primary completion

Feb 4, 2024

Study completion Feb 4, 2024

Sponsor

Sponsor type
Industry
First posted
Aug 6, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase I/II, open-label, first-in-human clinical study designed to evaluate the safety, tolerability, PK profile and efficacy of JS111 for patients with Non-small cell lung cance. This study is divided into 3 periods: dose escalation stage, dose extension stage, and efficacy extension stage.

Conditions

  • Lung Cancer

Interventions

  • JS111(AP-L1898 Capsules)Drug

    40 mg, QD

  • JS111(AP-L1898 Capsules)Drug

    80 mg, QD

  • JS111(AP-L1898 Capsules)Drug

    160 mg, QD

  • JS111(AP-L1898 Capsules)Drug

    240 mg, QD

  • JS111(AP-L1898 Capsules)Drug

    320 mg, QD

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety assessed by the adverse eventTime frame: up to 3 years
  2. Safety assessed by the serious adverse eventTime frame: up to 3 years
  3. Safety assessed by the physical examinatinTime frame: up to 3 years
  4. Safety assessed by the ECOG scoreTime frame: up to 3 years
  5. Safety assessed by the ophthalmic examinationTime frame: up to 3 years
  6. ORRTime frame: up to 3 years

Locations

37 sites in 1 country. Site status is shown where the registry gives one.

  • Hunan Cancer Hospital

    Changsha, China

  • Zhejiang Cancer Hospital

    Hangzhou, China

  • Shanghai Pulmonary Hospital

    Shanghai, China

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

  • Chinese People's Liberation Army Army Characteristic Medical Center

    Chongqing, Chongqing Municipality, China

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China

  • Sun Yat-sen Memorial Hospital ], Sun Yat-sen University

    Guangzhou, Guangdong, China

  • The First Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China

  • Cancer Hospital Chinese Academy of Medical Sciences,Shenzhen center

    Shenzhen, Guangdong, China

  • Affiliated Hospital of Guangdong Medical University

    Zhanjiang, Guangdong, China

  • Liuzhou People's Hospital

    Liuzhou, Guangxi, China

  • Harbin Medical University Cancer Hospital

    Haerbin, Heilongjiang, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China

  • Union Hospital Tongji Medical College Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology

    Wuhan, Hubei, China

  • Zhongnan Hospital of Wuhan University

    Wuhan, Hubei, China

  • Hubei Cancer Hospital

    Wuhan, Hubei, China

  • Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • The Second Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • The Affiliated Hospital of Inner Mongolia Medical University

    Hohhot, Inner Mongolia, China

  • North Jiangsu People's Hospital

    Yangzhou, Jiangsu, China

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

  • Jilin Cancer Hospital

    Changchun, Jilin, China

  • The First Hospital of China Medical University

    Shenyang, Liaoning, China

  • Liaoning Cancer Hospital

    Shenyang, Liaoning, China

  • Shandong Cancer Hospital

    Jinan, Shandong, China

  • Weifang People's Hospital

    Weifang, Shandong, China

  • Shanghai Oriental Hospital

    Shanghai, Shanghai Municipality, China

  • The First Affiliated Hospital of Xi'an Jiaotong University

    Xi’an, Shanxi, China

  • Yunnan Cancer Hospital

    Kunming, Yunnan, China

  • Hangzhou Cancer Hospital

    Hangzhou, Zhejiang, China

  • The First Affiliated Hospital , Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

  • The Second Affiliated Hospital Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

  • Sir Run Run Shaw Hospital Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

  • Taizhou Hospital of Zhejiang Province

    Taizhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.